R R

What Is an Orphan Drug?

An orphan drug is a drug or biological product developed for a rare disease or condition. In the United States, orphan designation can be granted when the disease generally affects fewer than 200,000 people or when development costs are not expected to be recovered from domestic sales. The designation applies to a specific drug and rare-disease use. It is intended to encourage development where the potential market might otherwise provide limited financial incentive.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is an Orphan Drug?

An orphan drug is a drug or biological product developed for a rare disease or condition. In the United States, orphan designation can be granted when the disease generally affects fewer than 200,000 people or when development costs are not expected to be recovered from domestic sales. The designation applies to a specific drug and rare-disease use. It is intended to encourage development where the potential market might otherwise provide limited financial incentive.

read more about orphan drug ...

Copy this HTML:

Copy HTML Copied!

How Does a Drug Receive Orphan Designation?

A sponsor submits scientific and prevalence information supporting the proposed rare-disease indication. The Food and Drug Administration reviews whether the disease and product meet the statutory and regulatory criteria. Designation can be requested before a marketing application is submitted. The same drug can have orphan designation for one use and non-orphan development for another.

What Incentives Can Orphan Designation Provide?

Orphan designation can qualify a sponsor for incentives such as tax credits for certain clinical testing, waiver of selected application fees, and eligibility for potential market exclusivity after approval. Grants and development support can also be available through separate programs. The incentives are intended to reduce barriers to studying small patient populations. They do not guarantee that development will succeed.

Does Orphan Designation Mean a Drug Is Approved?

No. Orphan designation is separate from approval or licensure. The product must still provide adequate evidence of quality, safety, and effectiveness through the applicable regulatory review. A designated drug can remain investigational, fail in clinical trials, or never receive approval. Approved orphan drugs follow the same scientific approval standards as other products.

What Are the Limits of Orphan Drug Development?

Rare diseases can have small, geographically dispersed, and clinically diverse patient populations. Limited natural-history data and a lack of validated outcome measures can complicate trial design. Manufacturing, recruitment, diagnosis, and long-term safety assessment can also be difficult. Orphan incentives support development but do not remove these scientific and operational challenges.

Frequently Asked Questions About Orphan Drugs

Does orphan drug status mean the medicine is approved?

No. Orphan designation recognizes a qualifying rare-disease development program, while approval requires a separate review of safety, effectiveness, and quality.

Why is it called an orphan drug?

The term reflects treatments that historically lacked sufficient commercial incentive for development because they served small patient populations. Incentive programs aim to reduce that development gap.

Can an approved medicine receive orphan designation for another use?

Yes. A previously approved drug can receive orphan designation for a qualifying rare-disease indication when the applicable criteria are met.

Do orphan drugs receive market exclusivity automatically?

No. Orphan designation provides eligibility, but orphan-drug exclusivity generally depends on approval for the designated rare-disease use and applicable legal requirements.

References

Rare Diseases at FDA. U.S. Food and Drug Administration. https://www.fda.gov/patients/rare-diseases-fda. Date Accessed August 6, 2026.

Designating an Orphan Product: Drugs and Biological Products. U.S. Food and Drug Administration. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products. Date Accessed August 6, 2026.

Frequently Asked Questions About Designating an Orphan Product. U.S. Food and Drug Administration. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/frequently-asked-questions-faq-about-designating-orphan-product. Date Accessed August 6, 2026.

Orphan Drug Act: Relevant Excerpts. U.S. Food and Drug Administration. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts. Date Accessed August 6, 2026.

Rare Diseases: Considerations for the Development of Drugs and Biological Products. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products. Date Accessed August 6, 2026.